John Stratton - Abbott Laboratories Director
ABT Stock | MXN 1,845 45.01 2.50% |
Director
Mr. John G. Stratton is Director of the Company since 2017.
Age | 57 |
Tenure | 7 years |
Phone | 224 667 6100 |
Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Rafael Anciola | Southern Copper | 57 | |
Indira Samarasekera | The Bank of | 65 | |
David Nicholson | Lloyds Banking Group | N/A | |
Jennifer Tippin | Lloyds Banking Group | N/A | |
Scott Bonham | The Bank of | 56 | |
Michael Penner | The Bank of | 48 | |
Melanie Healey | Verizon Communications | 56 | |
Peter Bonfield | Taiwan Semiconductor Manufactur | 74 | |
Benita Warmbold | The Bank of | 59 | |
Ronald Brenneman | The Bank of | 69 | |
Juan Colombas | Lloyds Banking Group | N/A | |
Reynold Levy | First Republic Bank | 71 | |
Michael Stein | McEwen Mining | 65 | |
George Parker | First Republic Bank | 78 | |
Luis Bonilla | Southern Copper | 58 | |
Richard Rexach | Verizon Communications | 63 | |
Paul Sobey | The Bank of | 58 | |
Alfredo Perez | Southern Copper | 65 | |
Donald Nicolaisen | Verizon Communications | 70 | |
Toby Strauss | Lloyds Banking Group | N/A | |
Eduardo Cortes | The Bank of | 64 |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.0882 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott White, Senior Vice President - International Nutrition | ||
Samuel Scott, Independent Director | ||
Deepak Nath, Senior Vice President - Abbott Vascular | ||
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
Mary Moreland, Ex HR | ||
Roger Bird, Senior Vice President - U.S. Nutrition | ||
Nancy McKinstry, Independent Director | ||
Heather Mason, Senior Vice President - Abbott Diabetes Care | ||
James Farrell, Independent Director | ||
Phebe Novakovic, Independent Director | ||
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets | ||
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
Roxanne Austin, Independent Director | ||
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
Stephen Fussell, Executive Vice President - Human Resources | ||
Thomas Freyman, Executive VP of Fin. and Admin. | ||
Sally Blount, Independent Director | ||
Daniel Starks, Independent Director | ||
Michelle Kumbier, Director | ||
Thomas Frinzi, Senior Vice President - Abbott Medical Optics | ||
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation | ||
John Capek, Executive VP of Ventures | ||
Robert Alpern, Independent Director | ||
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics | ||
Miles White, Chairman, CEO and Chairman of Executive Committee | ||
Robert Ford, Senior Vice President Diabetes Care. | ||
Glenn Tilton, Independent Director | ||
Elaine Leavenworth, VP Officer | ||
Richard Ashley, Executive VP of Corporate Devel. | ||
Michael Rousseau, President - Cardiovascular and Neuromodulation | ||
Edward Liddy, Independent Director | ||
Hubert Allen, Executive VP, General Counsel and Secretary | ||
Charles Foltz, Senior Vice President - Abbott Vascular | ||
Brian Yoor, CFO and Sr. VP of Fin. | ||
John Stratton, Director | ||
Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
Scott Leinenweber, Licensing Relations | ||
James Young, VP Officer | ||
Jared Watkin, Senior Vice President - Diabetes Care | ||
William Osborn, Independent Director | ||
Brian Blaser, Executive VP of Diagnostic Products | ||
Michael Warmuth, Executive Vice President - Established Pharmaceuticals | ||
Robert Funck, Vice President Controller | ||
Daniel Salvadori, Senior Vice President Established Pharmaceuticals, Latin America. | ||
Andrea Wainer, Ex Diagnostics | ||
Melissa Brotz, VP Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.0882 | |||
Profit Margin | 0.16 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 3.99 T | |||
Shares Outstanding | 1.74 B | |||
Shares Owned By Insiders | 0.73 % | |||
Shares Owned By Institutions | 75.70 % | |||
Price To Book | 5.44 X | |||
Price To Sales | 85.65 X |
Pair Trading with Abbott Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving against Abbott Stock
0.85 | TMN | Toyota Motor | PairCorr |
0.68 | SMSNN | Samsung Electronics | PairCorr |
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |